Halaven is a Intravenous Injection in the Human Prescription Drug category. It is labeled and distributed by Eisai Inc.. The primary component is Eribulin Mesylate.
| Product ID | 62856-389_3547d687-4951-4423-9fce-64fdac8635ed |
| NDC | 62856-389 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Halaven |
| Generic Name | Eribulin Mesylate |
| Dosage Form | Injection |
| Route of Administration | INTRAVENOUS |
| Marketing Start Date | 2010-11-15 |
| Marketing Category | NDA / NDA |
| Application Number | NDA201532 |
| Labeler Name | Eisai Inc. |
| Substance Name | ERIBULIN MESYLATE |
| Active Ingredient Strength | 1 mg/mL |
| Pharm Classes | Microtubule Inhibition [PE],Microtubule Inhibitor [EPC] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2022-12-31 |
| Marketing Start Date | 2010-11-15 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA201532 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 2010-11-15 |
| Ingredient | Strength |
|---|---|
| ERIBULIN MESYLATE | .5 mg/mL |
| SPL SET ID: | 31ce4750-ded5-4a0b-95e9-f229fa6bc822 |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 43624-002 | Halaven | eribulin mesylate |
| 62856-389 | Halaven | eribulin mesylate |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() HALAVEN 77886054 not registered Dead/Abandoned |
Eisai R&D Management Co., Ltd. 2009-12-04 |
![]() HALAVEN 77097283 3962019 Live/Registered |
Eisai R&D Management Co., Ltd. 2007-02-01 |